-Reuters
Related Posts
Barclays Maintains Overweight on Latham Group, Lowers Price Target to $23
Barclays analyst Matthew Bouley maintains Latham Group (NASDAQ:SWIM) with a Overweight and lowers the price target from $37 to $23.
Impact BioMedical Announces License Agreement With ProPhase Labs To Produce And Distribute Viral-Fighting Compound Equivir
Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE:DSS), along with its scientific research partner Global Research and Discovery Group Sciences (GRDG), announced today that it signed a license
Apple’s Newest Line Dominated iPhone Sales In Q1: What It Could Mean For Earnings
New research released ahead of Apple Inc's (NASDAQ: AAPL) March quarter results, due on April 28, points toward strong uptake for the latest iteration of its iPhones.